Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback